The Epilepsy indication potentially for MANF is new news as I don't recall that ever mentioned before. Here's a little different write up of the PR highlighting that.

https://epilepsynewstoday.com/2017/05/24/hera...-diseases/

MANF as a diagnostic has surfaced over the last few months that they mentioned. I don't think Amarantus has any patent on that potential, but having rights to composition of matter is key to all the indications for therapeutic.

I remember what Dr. Rubinfeld said back in 2012.

Quote:

---

"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."

---